Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients

NCT00562003 | Completed Phase 1 DMC

• 2 other identifiers: F061005016 (UAB 0643)UAB 0643
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of this study is to determine the maximally tolerated dose and spectrum of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally replicative adenovirus (Ad5-Delta 24RGD) in patients with recurrent ovarian cancer. Secondary objectives :

• To determine the biologic effects encountered with intraperitoneal delivery of Ad5-Delta 24RGD in patients with recurrent ovarian cancer cells
• To determine immunologic response generated against Ad5-Delta 24RGD when administered intraperitoneally to patients with recurrent ovarian adenocarcinoma
• To determine potential clinical activity of Ad5-Delta 24RGD when administered intraperitoneally to patients with recurrent ovarian adenocarcinoma

Conditions

Ovarian Cancer; Primary Peritoneal Cancer

Keywords

Ovarian cancer study

Outcome Measures

Primary Outcomes (1)

• To determine maximum tolerated dose and spectrum of toxicities of Ad5-Delta24RGD

  1 month

Secondary Outcomes (1)

• To determine biologic, immunologic, and anti-tumor effects of Ad5-delta24RGD

  1 month

Interventions

Tenckhoff Catheter placement PROCEDURE

'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.

Ad5-delta24RGD DRUG

Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed. The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'.

Eligibility Criteria

• Age: 19 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically documented invasive epithelial ovarian or extra-ovarian adenocarcinoma
• Patients must have persistent or recurrent disease after standard debulking/staging surgery and conventional chemotherapy.Prior chemotherapy must have included a taxane/platinum based regimen
• Patients must have evidence of intraabdominal disease; disease may be measurable or nonmeasurable
• Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy of greater than 3 months
• Patients must have adequate hematologic, renal, cardiac, pulmonary, coagulation, and hepatic function defined as:
• WBC\> 3,000 ul
• Granulocytes\> 1,500 ul
• Platelets\> 100,000
• Creatinine clearance (actual or calculated) \>80 mg/dl or serum creatinine \<2.0
• Serum transaminases \<2.5x upper limits of normal
• Normal serum bilirubin
• PT/PTT/INR \< 1.5 x institutional ULN
• Ejection fraction on echocardiogram \> 55%
• O2 saturation \> 92%
• Patients must be 19 years or older (as mandated by Alabama state law) and must have signed informed consent

You may not qualify if:

• Patients with epithelial ovarian tumors of low malignant potential (with or without invasive implants), with ovarian stromal tumors, or with germ cell tumors of the ovary are ineligible to participate in the study
• Patients with the only site of disease located beyond the abdominal cavity are ineligible to participate in the study
• Patients who are pregnant or lactating are ineligible to participate in the study
• Patients with a GOG performance status of 3 or 4 are ineligible to participate in the study
• Patients with active heart disease (characterized by angina, unstable arrhythmia, congestive heart failure or EF \< 55%, pulmonary hypertension), active or chronic debilitating pulmonary disease (i.e., active pneumonia, severe COPD, pulmonary edema, O2 saturation \< 92%), or coagulation disorders (i.e., bleeding disorders, on therapeutic anti-coagulants)

Sponsors & Collaborators

• University of Alabama at Birmingham: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

UAB Highlands, 1201 11th Ave S, 4th Floor, Gynecologic Oncology

Birmingham, Alabama, 35205, United States

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Ronald D Alvarez, M.D.

  The University of Alabama at Birmingham

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 20, 2007
• First Posted: November 21, 2007
• Study Start: June 1, 2007
• Primary Completion: May 1, 2009
• Study Completion: June 1, 2010
• Last Updated: January 26, 2011

Record last verified: 2011-01

Locations

US (1)